Bear Stearns Cuts Inveresk Research to 'Peer Perform'

Analyst Stephan Unger says the drug-development services provider's stock has risen 27% since reporting first-quarter results

Bear Stearns downgraded Inveresk Research (IRGI ) to peer perform from outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.